CN1049596C - Medicine composite for curing arthritis - Google Patents
Medicine composite for curing arthritis Download PDFInfo
- Publication number
- CN1049596C CN1049596C CN95119515A CN95119515A CN1049596C CN 1049596 C CN1049596 C CN 1049596C CN 95119515 A CN95119515 A CN 95119515A CN 95119515 A CN95119515 A CN 95119515A CN 1049596 C CN1049596 C CN 1049596C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- medicine
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicinal composition for treating arthritis, which comprises the components of atractylodes, radix paeoniae alba, liquorice, angelica, earthworm, radix achyranthis bidentatae, asarum herb, black-striped snake, processed aconite, cassia twig and pangolin, wherein 11 kinds of medicine is selected according to the proportion; the pangolin and the black-striped snake are pulverized into fine powders; the rest 9 kinds of medicine (the atractylodes, the radix paeoniae alba, the liquorice, the angelica, the earthworm, the radix achyranthis bidentatae, the asarum herb, the processed aconite and the cassia twig) is decocted two times by adding water; decoction liquid is combined two times, filtered and concentrated to thick paste; the fine powders are added to the thick paste, homogeneously stirred, dried at low temperature, pulverized, granulated in the way of ethanol as adhesives, dried and sized.
Description
The present invention relates to Chinese medicine composition, specifically a kind of pharmaceutical composition of treatment of arthritis.
Rheumatism and rheumatoid arthritis are frequently-occurring disease, according to foreign statistic only patient with rheumatoid arthritis just account for 2.5% of total man's mouth, by this supposition, in China's 1,100,000,000 populations, suffering from this patient has more than 3,000 ten thousand people.This disease course of disease is long, has the physician once to say abroad: " do not have a kind of disease, resemble arthritis and can make so many people like this, in the so long years, suffer so dull misery ".The Western medicine of this respect is a lot of at present, but toxicity is all very big, is not that gastrointestinal system is had stimulation, is exactly hemopoietic system is produced infringement.
The objective of the invention is in view of rheumatism and the rheumatoid arthritis course of disease long, the patient suffering is big, body constitution is empty, do not have problems such as appropriate therapeutic medicine, a kind of existing health-care effect is proposed, medicative again pharmaceutical composition, this pharmaceutical composition is through clinical verification, illustrate not only to have pain relieving, detumescence, prevent outside the abnormal effect, and has the disease-resistant effect of strong body, therefore, again pharmaceutical composition provided by the present invention is called the joint health.
It consists of pharmaceutical composition provided by the present invention:
Proportioning components (weight portion is represented) optimum ratio (weight portion is represented)
120 parts of Rhizoma Atractylodis Macrocephalae 100-140 parts
120 parts of Radix Paeoniae Alba 100-140 parts
40 parts of Radix Glycyrrhizae 30-50 parts
96 parts of Radix Angelicae Sinensis 80-100 parts
96 parts of Pheretima 80-100 parts
120 parts of Radix Achyranthis Bidentatae 100-140 parts
40 parts of Herba Asari 20-60 parts
96 parts of Zaocys 80-100 parts
64 parts of Radix Aconiti Lateralis Preparata 50-70 parts
120 parts of Ramulus Cinnamomi 100-140 parts
80 parts of Squama Manis 60-100 parts
The rheumatic fever of modern medicine, gout, rheumatic arthritis, lumbar muscle strain, scapulohumeral periarthritis, hyperosteogeny etc. all belong to the arthromyodynia scope." numbness " promptly hinders and closes obstructed meaning.QI and blood can not be unimpeded after human body flesh table, meridians are soaked by exopathogen to attack, thereby cause that limbs, joint, muscle etc. locate class illness such as pain, miserable, heavy, numbness, all is called arthromyodynia.The generation of primary disease, endogenous cause of ill are insufficiency of vital energy and bloods, the Wei Bugu of battalion, and exopathogenic factor and weather conditions, living environment are relevant, and wind and cold three heresies that wet are taken advantage of a weak point.So recipes for Saving Lives is said: " all because of body void, space between skin and muscles is empty, and the dampness of having a cold forms numbness also ".Jing-Yue Complete Works is said: " numbness person closes also, is closed by evil with vim and vigour, must not pass through and disease also ".In a word, the cause of disease of primary disease is owing to body void, the damp that is affected by the cold invasion and attack, and the muscle that flows away, the joint, meridians, so that QI-blood circulation is not smooth, hinders and obstructed forming.Wet three gas of wind and cold mostly and close but often win to some extent partially, so the also difference to some extent of clinical disease, general domination of wind is to go, and numbness, domination of cold are arthralgia aggravated by cold, and domination of damp pathogen is a damp arthralgia.As the plain body deficiency of YIN, in intrinsic heat is arranged, the damp that is affected by the cold, it is hurried to fall ill, and the obvious person of domination of heat disease is a pyretic arthralgia.By cold-damp three heresies are arranged, the meridians of being detained are not prolongedly healed, and are strongly fragrant and heat-transformation also can transfer pyretic arthralgia to.The traditional Chinese medical science is to the dialectical rule of treatment of arthromyodynia, and migratory arthralgia is based on dispelling wind and removing obstruction in the collateral, and assistant is with the wind dampness removing that looses; Arthralgia aggravated by cold is based on dispelling cold by warming the meridian, and assistant is with the removing dampness medicine that dispels the wind; The damp arthralgia the spleen strengthening and damp drying, assistant is with the medicine of expelling wind and cold; The pyretic arthralgia rule of treatment is the heat clearing away collateral dredging, the dispelling wind damp eliminating; All arthromyodynias are deficiency of both the liver and kidney with the passing of time, sees the soreness of waist, and lower limb is soft, diseases such as spasm of muscles and vessels, and available liver and kidney tonifying etc. are approximately.
Therefore, according to above-mentioned analysis to arthritis pathology, the pharmaceutical composition that provides of the present invention is a principal agent with Pheretima, Zaocys, wherein these two kinds of medicines can " heat clearing away arresting convulsion, collateral dredging, diuresis ", cure mainly arthralgia, numb limbs and tense tendons, diseases such as hemiplegia, in addition Zaocys again can " dispel the wind, collateral dredging, relieving convulsion; can be used for rheumatoid arthritis stubborn, diseases such as numbness contracture ", as seen this ministerial drug all has the effect of treatment arthromyodynia, and the effect of dispelling wind and removing obstruction in the collateral is all arranged, share together and can play collaborative effect.Ministerial drug is Radix Achyranthis Bidentatae, Squama Manis, Radix Aconiti Lateralis Preparata, Ramulus Cinnamomi, and its structure is monarch's two ministers four; Radix Achyranthis Bidentatae removing blood stasis blood wherein, the meridian dredging, having can conducting blood to flow downwards, has a pain for rheumatic arthralgia, joint contracture and blood stasis, and the effect of removing obstruction in the collateral to relieve pain is all arranged; The Squama Manis promoting blood circulation to remove obstruction in the collateral, the sharp joint of Shujin; Radix Aconiti Lateralis Preparata, Ramulus Cinnamomi temperature three-way meridian, dispersing cold for relieving pain.Radix Angelicae Sinensis, the Rhizoma Atractylodis Macrocephalae, the Radix Paeoniae Alba, Herba Asari are adjuvant drug, and Radix Angelicae Sinensis both can have been strengthened the promoting the circulation of blood effect of invigorating blood circulation of medicines such as Radix Achyranthis Bidentatae, can combine the promoting the circulation of QI to relieve pain effect of playing again with principal agent and Herba Asari, and can enrich blood; Rhizoma Atractylodis Macrocephalae the spleen strengthening and damp drying; The Radix Paeoniae Alba and Ramulus Cinnamomi associating have He Yingwei, and the gas effect activates yang.Secondly the Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, Radix Glycyrrhizae and the Rhizoma Atractylodis Macrocephalae, Radix Angelicae Sinensis, Radix Achyranthis Bidentatae are collaborative can be used as messenger drug and treats, can priming descending because of Radix Glycyrrhizae, goes into kidney, reinforcement the kidney invigorating cold relieving, the effect of strengthening bone and muscle.
The production method of pharmaceutical composition provided by the present invention is:
Choose ten Herba indigoferae Pseudotinctoriae by described proportioning, with Squama Manis, Zaocys is ground into fine powder, and all the other nine flavor medicines (Rhizoma Atractylodis Macrocephalae, the Radix Paeoniae Alba, Radix Glycyrrhizae, Radix Angelicae Sinensis, Pheretima, Radix Achyranthis Bidentatae, Herba Asari, Radix Aconiti Lateralis Preparata, Ramulus Cinnamomi) decoct with water twice, add 10 times of amounts of water for the first time, fry in shallow oil 2 hours; For the second time add 8 times of amounts of water, fried in shallow oil 1.5 hours, merge decocting liquid twice, filter, be concentrated into relative density and be the thick paste of 1.30g/mL (60 ℃ time), above-mentioned fine powder is added in the thick paste, stir, dry, the pulverizing of low temperature (below 80 ℃) is made binding agent with ethanol and is granulated, dry, granulate.Dress up the heavy capsule of 0.3g promptly for every.Differentiate that this product is the dark-brown powder, sour-puckery flavor, little hardship.1. this product powder, microscopically is observed: the scute fragment is colourless, and circular hole differs in size; Irregular meat fiber piece sheet is faint yellow or closely colourless, is densely covered with neat like the ripple reason.2. get this product, soak, filtrate after treatment, speckle is blue purple, 3. this product powder, adds water-saturated n-butanol and grinds, after with positive fourth ferment evaporate to dryness, residue adds dissolve with methanol, mixes neutral alumina, in layer folding post of packing into, with aminoform-methanol-eluted fractions, evaporate to dryness, use dissolve with methanol, as need testing solution.Get paeoniflorin and compare product,, show identical blue purple mottle according to the thin layer chromatography test.4. get this product powder, add Ethanol Treatment, filter, reclaim ethanol to 5ml, as need testing solution, other gets Radix Angelicae Sinensis and compares medical material, and is treated, and medical material solution according to the thin layer chromatography test, shows identical bright blue white fluorescent speckle in contrast.
Its pharmacological tests of the pharmaceutical composition of treatment of arthritis provided by the present invention is:
(1) preclinical pharmacology test
1, pharmaceutical composition is to the antiinflammatory action of rat granuloma model: experimental result shows, pharmaceutical composition and hydrocortisone blank are relatively, can significantly alleviate the swollen weight of rat granuloma, but the effect that hydrocortisone inhibition granuloma forms is more remarkable.
2, the pharmaceutical composition on Carrageenan causes the effect of rat arthritis disease; Experimental result shows that heavy dose of group of pharmaceutical composition and middle dosage group significantly suppress carrageenin and cause the rat paw edema effect.Illustrate that pharmaceutical composition has the effect that the antagonism carrageenin causes inflammatory reaction.
3, the analgesic activity of pharmaceutical composition: hot plate method: large, medium and small three the dosage groups of pharmaceutical composition significantly improve the mice pain threshold values that thermostimulation causes.Proof, pharmaceutical composition has certain analgesic activity.Writhing method: health big or middle dosage group in joint significantly improves mice analgesia percentage rate.
4, the endurance effect of pharmaceutical composition: use the swimming method, large, medium and small dosage group of pharmaceutical composition and matched group compare, and obviously prolong mouse diing time, show that pharmaceutical composition has significant antifatigue effect to mice.
5, the resisting oxygen lack of pharmaceutical composition: the heavy dose of group of pharmaceutical composition compares P＜0.05 with matched group, and the joint health can prolong the mice time-to-live, has certain resisting oxygen lack.
6, the cold-resistant experiment of pharmaceutical composition: the result shows the death time of the cold-resistant experiment of the equal energy of large, medium and small three the dosage groups of pharmaceutical composition significant prolongation mice, proves that pharmaceutical composition has the effect of enhancing body resisting cold ability.
7, the joint is very to effect of immunologic function: do two altogether: promptly the mice serum antibody horizontal detects (hemolysin product algoscopy) and lymphproliferation response experiment (MMT colorimetry), the result shows, health big or middle dosed administration in joint can suppress mouse antibodies and produce, reduce hemolysin product in the serum, and lymphproliferation response is reduced, relatively there were significant differences with normal saline, but effect is starkly lower than cyclophosphamide, low dose of administration and NS group zero difference.The result shows that pharmaceutical composition is to the inhibitory action of immune function of mice tool.
8, pharmaceutical composition is to the relevant effect of rat assist agent arthritis: the heavy dose of group of pharmaceutical composition and blank group are relatively, constitutional and secondary lesion that adjuvant is caused have remarkable inhibitory action (P＜0.05), and the dosage group is compared with blank in the health of joint; The primary lesion that adjuvant is caused has obvious inhibitory action (P＜0.05).
9, pharmaceutical composition is to the influence of rabbit skin hair cell vascular permeability: big or middle dosage group of pharmaceutical composition and the comparison of blank group can make histamine cause that the blued area that is caused by azovan blue of rabbit significantly dwindles, and skin indigo plant dyes between now and prolongs.Show that pharmaceutical composition has the pharmacological action that suppresses rabbit skin capillary permeability.
10, pharmaceutical composition is to the microcirculatory influence of rat mesentery: rat mesentery capillary blood flowing velocity can be significantly accelerated in big or middle dosage group of pharmaceutical composition and matched group comparison, but its expansion capillary action is not remarkable.Show that this medical instrument has the pharmacological action of the microcirculation of rats of improvement.
(2) anxious, long poison experiment
1, acute toxicity testing: 20 of Kunming mouses of experiment, body weight 19 ± 3.0g, gastric infusion.Pharmaceutical composition is condensed into 50% suspension, dosage 0.2g/10.0g, twice on the one, logotype 7 days, none dead mouse takes off cervical vertebra with whole mices after 7 days and puts to death, carry out obduction, do not find that internal organs such as the animal heart, liver, lung, kidney, stomach have remarkable abnormal phenomena.Show that the pharmaceutical composition maximum tolerated dose is greater than 20.0/kg.
2, pharmaceutical composition long term toxicity test: experimental result proof pharmaceutical composition is observed continuous 3 months long term toxicity tests of rat with large, medium and small 3 various dose groups.The result shows that large, medium and small 3 the dosage groups of pharmaceutical composition after the 75th day, can make rat body weight be starkly lower than control rats in long term administration.After 3 months, middle dosage, low dose are not found tangible toxic reaction to pharmaceutical composition in long term administration.
Its clinical test results of pharmaceutical composition provided by the present invention is:
Its clinical trial of I:
Observe 50 examples altogether, take self-controlled method to carry out the clinical observation test.Man 8 people, women 42 people.The oldest person 64 years old, reckling 16 years old.The elder of the course of disease 22 years, the shortest person 3 months.Result of the test, 30 examples of fully recovering (60.0%), produce effects 11 examples (22.0%), effective 8 examples (16.0%), total effective rate 98.0%.
II phase clinical research:
We answer medicament composition capsule, the grouping of employing stochastic sampling, the method of own control has been carried out the II clinical trial phase in first and second Affiliated Hospital of Xian Medical Univ, the attached institute in Provincial Medicine Research Institute, four tame units of The People's Hospital, and to select ZHUANGGU GUANJIE WAN be the matched group medication.It observes case 390 examples, and wherein 300 examples are organized in treatment, matched group 90 examples.Observed result, treatment are organized total produce effects 56.0%, and total effective 94.3%; The total produce effects 31.1% of matched group, 79.7%, two group of aggregate efficiency of total effective rate has highly significant difference (P＜0.01), and there were significant differences for total effective rate (P＜0.05).Secondly, pharmaceutical composition is not found untoward reaction and toxic and side effects in application process, the said preparation effective and safe is described.
Use the pharmaceutical composition of this kind treatment of arthritis provided by the present invention, diseases such as diagnosis and treatment arthritis effectively can be played the effect of logical active, the promoting blood circulation to remove blood stasis of benefiting QI and nourishing blood, bone and muscle strengthening, temperature, expelling wind and dampness, alleviating pain and detumescence.
Embodiment 1
Choose ten Herba indigoferae Pseudotinctoriae by following proportioning:
Proportioning components (weight portion is represented)
100 parts of the Rhizoma Atractylodis Macrocephalaes
100 parts of the Radix Paeoniae Albas
30 parts in Radix Glycyrrhizae
80 parts of Radix Angelicae Sinensis
80 parts of Pheretimas
100 parts of Radix Achyranthis Bidentataes
20 parts of Herba Asaris
80 parts of Zaocys
50 parts of Radix Aconiti Lateralis Preparata
100 parts of Ramulus Cinnamomi
60 parts of Squama Maniss
Production method is: with Squama Manis, Zaocys is ground into fine powder, and all the other nine flavor medicines (Rhizoma Atractylodis Macrocephalae, the Radix Paeoniae Alba, Radix Glycyrrhizae, Radix Angelicae Sinensis, Pheretima, Radix Achyranthis Bidentatae, Herba Asari, Radix Aconiti Lateralis Preparata, Ramulus Cinnamomi) decoct with water twice, add 10 times of amounts of water for the first time, fry in shallow oil 2 hours; For the second time add 8 times of amounts of water, fried in shallow oil 1.5 hours, merge decocting liquid twice, filter, be concentrated into relative density and be the thick paste of 1.30g/mL (60 ℃ time), above-mentioned fine powder is added in the thick paste, stir, dry, the pulverizing of low temperature (below 80 ℃) is made binding agent with ethanol and is granulated, dry, granulate.
Embodiment 2
Choose ten Herba indigoferae Pseudotinctoriae by following proportioning:
Proportioning components (weight portion is represented)
140 parts of the Rhizoma Atractylodis Macrocephalaes
140 parts of the Radix Paeoniae Albas
50 parts in Radix Glycyrrhizae
100 parts of Radix Angelicae Sinensis
100 parts of Pheretimas
140 parts of Radix Achyranthis Bidentataes
60 parts of Herba Asaris
100 parts of Zaocys
70 parts of Radix Aconiti Lateralis Preparata
140 parts of Ramulus Cinnamomi
100 parts of production methods of Squama Manis are identical with embodiment 1.Embodiment 3 chooses ten Herba indigoferae Pseudotinctoriae by following proportioning:
Proportioning components (weight portion is represented)
120 parts of the Rhizoma Atractylodis Macrocephalaes
120 parts of the Radix Paeoniae Albas
40 parts in Radix Glycyrrhizae
96 parts of Radix Angelicae Sinensis
96 parts of Pheretimas
120 parts of Radix Achyranthis Bidentataes
40 parts of Herba Asaris
96 parts of Zaocys
64 parts of Radix Aconiti Lateralis Preparata
120 parts of Ramulus Cinnamomi
80 parts of production methods of Squama Manis are identical with embodiment 1.
Claims (3)
1, a kind of pharmaceutical composition of treatment of arthritis wherein, consists of:
Composition parts by weight proportioning
100 parts of the Rhizoma Atractylodis Macrocephalaes
100 parts of the Radix Paeoniae Albas
30 parts in Radix Glycyrrhizae
80 parts of Radix Angelicae Sinensis
80 parts of Pheretimas
100 parts of Radix Achyranthis Bidentataes
20 parts of Herba Asaris
80 parts of Zaocys
50 parts of Radix Aconiti Lateralis Preparata
100 parts of Ramulus Cinnamomi
60 parts of Squama Maniss.
2, the described pharmaceutical composition of claim 1 wherein, consists of:
Composition parts by weight proportioning
140 parts of the Rhizoma Atractylodis Macrocephalaes
140 parts of the Radix Paeoniae Albas
50 parts in Radix Glycyrrhizae
100 parts of Radix Angelicae Sinensis
100 parts of Pheretimas
140 parts of Radix Achyranthis Bidentataes
60 parts of Herba Asaris
100 parts of Zaocys
70 parts of Radix Aconiti Lateralis Preparata
140 parts of Ramulus Cinnamomi
100 parts of Squama Maniss.
3, the described pharmaceutical composition of claim 1 wherein, consists of:
Composition parts by weight proportioning
120 parts of the Rhizoma Atractylodis Macrocephalaes
120 parts of the Radix Paeoniae Albas
40 parts in Radix Glycyrrhizae
96 parts of Radix Angelicae Sinensis
96 parts of Pheretimas
120 parts of Radix Achyranthis Bidentataes
40 parts of Herba Asaris
96 parts of Zaocys
64 parts of Radix Aconiti Lateralis Preparata
120 parts of Ramulus Cinnamomi
80 parts of Squama Maniss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95119515A CN1049596C (en) | 1995-12-18 | 1995-12-18 | Medicine composite for curing arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95119515A CN1049596C (en) | 1995-12-18 | 1995-12-18 | Medicine composite for curing arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1132642A CN1132642A (en) | 1996-10-09 |
| CN1049596C true CN1049596C (en) | 2000-02-23 |
Family
ID=5082037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95119515A Expired - Fee Related CN1049596C (en) | 1995-12-18 | 1995-12-18 | Medicine composite for curing arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1049596C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327886C (en) * | 2005-01-20 | 2007-07-25 | 曹清华 | Pharmaceutical composition for treating arthritis and method for preparing the same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306526A (en) * | 2014-10-15 | 2015-01-28 | 陶伟 | Traditional Chinese medicine composition for treating brachial plexus neuritis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1061158A (en) * | 1991-01-31 | 1992-05-20 | 伊卫国 | The manufacture method of specially medicinal liquor for rheumatism |
-
1995
- 1995-12-18 CN CN95119515A patent/CN1049596C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1061158A (en) * | 1991-01-31 | 1992-05-20 | 伊卫国 | The manufacture method of specially medicinal liquor for rheumatism |
Non-Patent Citations (3)
| Title |
|---|
| 内蒙古中医药1990,11(2) 1990.2.28 周乃玉，"痹玉康"治疗类风湿性关节炎的临床研究-附126例临床总结 * |
| 河北中医1992,14(4) 1992.4.30 檀骏翔，自拟关节舒治疗类风湿性关节炎135例临床分析 * |
| 河北中医1992,14(4) 1992.4.30 檀骏翔，自拟关节舒治疗类风湿性关节炎135例临床分析;内蒙古中医药1990,11(2) 1990.2.28 周乃玉，"痹玉康"治疗类风湿性关节炎的临床研究-附126例临床总结 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327886C (en) * | 2005-01-20 | 2007-07-25 | 曹清华 | Pharmaceutical composition for treating arthritis and method for preparing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1132642A (en) | 1996-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103007191B (en) | Chinese medicinal composition for treating jaundice | |
| CN101390994B (en) | Medicine for treating herpes zoster | |
| CN1803187A (en) | Chinese herbal medicine for treating lumbar intervertebral disk protrusion and hyperosteogeny | |
| CN1966003A (en) | Externally applied medicament for treating rheumatism | |
| CN1286518C (en) | Chinese medicinal prescription for treating gastropathy | |
| CN104606582A (en) | Traditional Chinese medicine formula for treating anemofrigid-damp arthralgia | |
| CN103920074A (en) | Traditional Chinese medicine composition for treating hepatitis B | |
| CN101690768B (en) | Vein and artery relieving pills for impediment of sinew | |
| CN1317021C (en) | Chinese medicinal formulation for stopping pain for removing Bi | |
| CN102106980B (en) | Medicament for treating uremia and preparation method thereof | |
| CN101940759B (en) | Chinese medicinal composition for treating liver diseases and preparation method and application thereof | |
| CN1883533A (en) | Pharmaceutical composition for treating apoplexy and preparation method thereof | |
| CN1049596C (en) | Medicine composite for curing arthritis | |
| CN101940758B (en) | Traditional Chinese medicinal composition for treating liver diseases, preparation method thereof and application thereof | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN101199749A (en) | Chinese medicine for treating AIDS | |
| CN100402065C (en) | Capsule for treating gout and preparation process thereof | |
| CN106237155A (en) | A kind of decoction medicine treating exogenous high fever and preparation method thereof | |
| CN111228388A (en) | A pharmaceutical composition for treating hepatopathy, and its application method | |
| CN1059574C (en) | Chinese medicine preparation | |
| CN106668787A (en) | Traditional Chinese medicine honeyed pill for treating hepatonecrosis and liver cancer and preparation method of traditional Chinese medicine honeyed pill | |
| CN106692588A (en) | Traditional Chinese medicine formula for treating liver cirrhosis | |
| CN102949684B (en) | Medicine formula for treating rheumatoid arthritis | |
| CN1309412C (en) | Medicine composition for treating AIDS and preparing method thereof | |
| CN1310669C (en) | Medicine composition for treating chronic hepatitis and its prepn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |